Rockwell Medical, Inc. (RMTI) Stock Price & Analysis
Rockwell Medical, Inc. (RMTI) closed at USD 7.98 on Thursday, October 15, 2026, up 3.64% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 7.7; the Oct 15, 2026 session ranged USD 7.36–8.24 on volume of 79,288 shares. Market capitalization is $32.16M, with a 52-week range of USD 4.89–12.9 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RMTI.md
Key facts (RMTI)
- Analysts: Buy (mean 1.50 on a 1–5 scale) (2 analysts), mean target USD 20 (range 20–20).
- Total return with dividends: 1Y -32.9% vs S&P 500 +18.1%; 5Y -87.9% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.18, revenue estimate $18.2M.
Analysts (RMTI)
Consensus Buy (mean 1.50 on a 1–5 scale), 2 analysts; mean target USD 20 (low 20, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-11 | HC Wainwright & Co. | Reiterated | Buy | $20 |
| 2026-07-09 | HC Wainwright & Co. | Target raised | Buy | $2 → $20 |
Total return (dividends reinvested) (RMTI)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -32.9% | -87.9% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -33.0% | -34.4% |
| Volatility (annualized) | 65.5% | 94.6% |
| Max drawdown | -58.8% (Jan 2026→Jul 2026) | -91.6% (Oct 2021→Jun 2026) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 7.98 |
|---|---|
| Change | ▲ 3.64% (up) |
| Previous Close | USD 7.7 |
| Open | USD 7.76 |
| Day Range | USD 7.36 – 8.24 |
| 52-Week Range | USD 4.89 – 12.9 |
| Volume | 79,288 shares |
| Market Cap | $32.16M |
| Exchange | NCM |
Technical Analysis (RMTI)
Nexqual's technical model rates RMTI "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 47.16 (neutral) |
| vs SMA50 | Above (USD 7.96) |
| MACD | -0.05 (negative) |
Analyst Ratings (RMTI)
Wall Street analysts rate RMTI "Buy" based on 2 analysts, with a mean price target of USD 20 (range USD 20–20), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 20 |
| High Target | USD 20 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (RMTI)
| Next Earnings Date | 2026-11-12 |
|---|---|
| Revenue Estimate | $18.22M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.34 vs est -0.24 ▼ miss |
| 2026-03-31 | USD -0.4 vs est -0.25 ▼ miss |
| 2025-12-31 | USD -0.1 vs est 0.2 ▼ miss |
| 2025-09-30 | USD -0.5 vs est -0.45 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (RMTI)
| Total Revenue | $69.39M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +10.60% |
| Gross Margin | +17.71% |
| Operating Margin | -5.97% |
| Profit Margin | -7.33% |
| ROE | -15.53% |
| Debt / Equity | 0.4 |
| Current Ratio | 3.25 |
| Total Cash | $24.80M |
| Total Debt | $13.93M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (RMTI)
Nexqual rates Rockwell Medical, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Critical — Revenue -32% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Gross margin 18%, operating -6% |
| Balance Sheet | Strong — $25M cash vs $14M debt, net cash position |
| Cash Flow | Solid — Operating cash flow $3M (TTM) |
| Efficiency | Critical — ROE -16%, ROA -5.2% |
Ownership (RMTI)
| Insider Ownership | +14.78% |
|---|---|
| Institutional Ownership | +8.52% |
| Shares Outstanding | 4.03M |
| Float | 3.59M |
| Short % of Float | +1.80% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (RMTI)
Rockwell Medical, Inc. is led by Mark Strobeck (age 54), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| President, CEO & Director | Mark Strobeck (age 54) |
|---|---|
| Senior VP & CFO | Jesse Neri (age 47) |
| Senior VP & COO | Heather H. Hunter (age 46) |
Major Backers & Investors (RMTI)
Notable institutional backers of Rockwell Medical, Inc. include Renaissance Technologies, Fidelity, Jane Street Group, LLC, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Renaissance Technologies | 0.89% |
| Fidelity | 0.79% |
| Jane Street Group, LLC | 0.61% |
| Harbour Investments, Inc. | 0.54% |
| Wealthspire Advisors, LLC | 0.38% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.68% |
| Geode Capital | 0.9% |
| BlackRock | 0.36% |
| State Street | 0.25% |
| Northern Trust | 0.23% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BHC | Bausch Health Companies Inc. | USD 6.31 | ▲ 7.13% |
| HCM | HUTCHMED (China) Limited | USD 13.94 | ▲ 3.26% |
| LQDA | Liquidia Corporation | USD 34.78 | ▲ 29.73% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.65 | ▲ 2.98% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 33.62 | ▼ 5.08% |
| RGC | Regencell Bioscience Holdings L | USD 9.52 | ▲ 16.24% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt